Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cybin (CYBN)
:CYBN
CYBN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.50 - $19.83
Previous Close$9.5
Volume184.55K
Average Volume (3M)296.04K
Market Cap
$1.38M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Jun 25, 2025EPS Estimate
-0.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding21,026,426
10 Day Avg. Volume361,999
30 Day Avg. Volume296,042
Standard Deviation1.11
R-Squared0.08
Alpha0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$82.67Price Target Upside786.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Cybin News
PremiumCompany Announcements
Cybin Accelerates PARADIGM Program for Depression Treatment
PremiumCompany Announcements
Cybin Partners with Segal Trials for Pivotal Phase 3 Program---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsCYB003 has received Breakthrough Therapy Designation from the FDA, which might accelerate its path to potential approval.
Efficacy And SafetyPhase 2 data for CYB003 demonstrated unprecedented durability of effect in major depressive disorder, which could differentiate it from standard antidepressants.
Market PotentialEncouraging data generated so far with CYB003 in major depressive disorder, which is a large market, leads to the view that CYBN is undervalued.
Bears Say
Financial PerformanceHigher operating expenses than expected were driven by increased clinical trial activity, impacting financial models.
Potential RisksPotential for dilution exists with most clinical-stage biopharma companies, including CYBN, due to ongoing trials and future capital requirements.
Stock ValuationThere has been a moderate decrease in the price target for Cybin shares, reflecting updated estimates and competitive dynamics in the psychedelics space.
---
Ownership Overview
Currently, No data available
---
CYBN FAQ
What was Cybin’s price range in the past 12 months?
Cybin lowest stock price was $6.50 and its highest was $19.83 in the past 12 months.
What is Cybin’s market cap?
Cybin’s market cap is $1.38M.
When is Cybin’s upcoming earnings report date?
Cybin’s upcoming earnings report date is Jun 25, 2025 which is in 124 days.
How were Cybin’s earnings last quarter?
Cybin released its earnings results on Feb 11, 2025. The company reported -$0.373 earnings per share for the quarter, beating the consensus estimate of -$0.74 by $0.366.
Is Cybin overvalued?
According to Wall Street analysts Cybin’s price is currently Undervalued.
Does Cybin pay dividends?
Cybin does not currently pay dividends.
What is Cybin’s EPS estimate?
Cybin’s EPS estimate is -0.81.
How many shares outstanding does Cybin have?
Cybin has 21,026,426 shares outstanding.
What happened to Cybin’s price movement after its last earnings report?
Cybin reported an EPS of -$0.373 in its last earnings report, beating expectations of -$0.74. Following the earnings report the stock price went up 0.213%.
Which hedge fund is a major shareholder of Cybin?
Currently, no hedge funds are holding shares in CYBN
---
Company Description
Cybin
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
---
CYBN Stock 12 Month Forecast
Average Price Target
$82.67
▲(786.07% Upside)
Technical Analysis
Mydecine Innovations Group
―
Numinus Wellness
―
Red Light Holland
―
Entheon Biomedical
―
HAVN Life Sciences
―
Best Analysts Covering CYBN
1 Year
1 Year Success Rate
2/23 ratings generated profit
1 Year Average Return
-28.91%
reiterated a buy rating 9 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 8.70% of your transactions generating a profit, with an average return of -28.91% per trade.
---